Report Company Directory

AquaVenture Holdings

• Raymond James Afternoon Notes by Raymond James
• WAAS | Dropping Coverage as Buyout Closes; To Continue Playing Desal, We Remain Fans of ERII by Raymond James
• Morning Brew - March 6, 2020 by Raymond James
• Raymond James Morning Notes - COO, COST, GMS, TCF by Raymond James
• WAAS | Buyout by Culligan Nears Closing. Want to Stay Invested in Desal? Take a Look at ERII by Raymond James
• Raymond James Afternoon Notes - CMBM, KBH by Raymond James
• Raymond James Energy Daily Update by Raymond James
• Raymond James Morning Notes - AEIS, AMRC, AQUA, EVA, GTLS, ITRI, ORCC by Raymond James
• Clean Tech 4Q19 Update: Decarbonization and ESG Spur Best Year Since 2013; Raising Six Target Prices by Raymond James
• Raymond James Morning Notes - CLNE by Raymond James

Aquesta Financial Holdings Inc

• Aquesta Financial Holdings, Inc Announces Results of Operations for the First Quarter of 2021 by GlobeNewsWire
• Aquesta Financial Holdings, Inc. Announces Results of Operations for the Second Quarter of 2021 and Declares Annual Cash Dividend of 14 Cents Per Share by GlobeNewsWire
• UCBI | Announces Acquisition with a Tribe Called (A)quest(a) by Raymond James
• Aquesta Financial Holdings, Inc Announces Results of Operations for the Fourth Quarter of 2020 by GlobeNewsWire
• Aquesta Financial Holdings, Inc., Announces Eighth Consecutive Annual Cash Dividend by GlobeNewsWire
• Aquesta Financial Holdings, Inc Announces Results of Operations for the Third Quarter of 2020 by GlobeNewsWire
• Aquesta Financial Holdings, Inc Announces Results of Operations for the Second Quarter of 2020 by GlobeNewsWire
• Aquesta Financial Holdings, Inc Announces Results of Operations for the First Quarter of 2020 by GlobeNewsWire
• Aquesta Bank Funds First Payroll Protection Program Loan with Local Client by GlobeNewsWire
• Aquesta Financial Holdings, Inc Announces Results of Operations for the Fourth Quarter of 2019 by GlobeNewsWire

Aquestive Therapeutics

• Aquestive Therapeutics Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm™ by GlobeNewsWire
• Aquestive Therapeutics to Participate in Upcoming September Investor Conferences by GlobeNewsWire
• Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock by GlobeNewsWire
• Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ (epinephrine) Sublingual Film by GlobeNewsWire
• Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update by GlobeNewsWire
• Aquestive Therapeutics to Report Second Quarter 2025 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET by GlobeNewsWire
• Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer by GlobeNewsWire
• Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ (epinephrine) Sublingual Film by GlobeNewsWire
• Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism by GlobeNewsWire
• Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit by GlobeNewsWire

Aquila

• Ford Equity International Rating and Forecast Report by Ford Equity Research

AQUILA ACQUISITION CORP